Valeant Makes Its First Acquisition Move Of The Year, In Dermatology
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant Pharmaceuticals will continue its march into dermatology with the acquisition of PreCision Dermatology for $475 million in cash plus milestones. The deal represents a bolt-on opportunity for Valeant, which will leverage its existing infrastructure to sell PreCision’s products.
You may also be interested in...
Valeant Has Big Plans To Become A Big Pharma In Coming Year
The Canadian specialty pharma has been buying up companies left and right and has plans to continue in 2014, even possibly pursuing a merger of equals in an effort to more than double its market capitalization.
Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis
The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.